Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx Inc (CDNA) delivers innovative non-invasive diagnostics for transplant patient care through advanced genomics and bioinformatics. This news hub provides investors and healthcare professionals with essential updates on the company's developments in precision medicine.
Key resources include: Earnings reports detailing financial performance in transplant diagnostics, regulatory updates on FDA-cleared testing solutions, and strategic partnership announcements expanding into hematology oncology. Track clinical trial outcomes validating AlloSure® monitoring and discover operational milestones in digital health integration.
Our curated collection enables efficient tracking of CDNA's progress in reducing invasive biopsies through blood-based dd-cfDNA analysis. Stay informed about innovations in kidney, heart, and lung transplant surveillance technologies that are reshaping organ rejection management.
Bookmark this page for real-time updates on CareDx's evidence-based diagnostic solutions and their impact on transplant care standards. Verify analysis dates and consult official filings for complete context on all developments.
CareDx, a precision medicine company, announced that its Chairman and CEO, Peter Maag, will present at the AAKP and George Washington University summit on July 16-17, 2020. The event focuses on innovations in kidney disease, particularly the role of artificial intelligence in transplant care. CareDx aims to enhance patient care through its digital tools, AiTraC and AlloCare, which address information management challenges for transplant patients. The summit highlights the global interest in improving transplant outcomes through data-driven solutions.
CareDx, Inc. (Nasdaq: CDNA) announced the publication of a study in Kidney360 evaluating its AlloSure tool against another monitoring method for kidney transplant rejection. The study, involving 76 patients, indicated that AlloSure provides faster results, with 75% of results delivered at least one day earlier than its counterpart, demonstrating superior accuracy in clinical interpretation. This validation highlights AlloSure's effectiveness in addressing transplant-specific testing needs.
CareDx (Nasdaq: CDNA) announced the full exercise of underwriters' option to purchase an additional 585,937 shares at $32.00 per share, resulting in net proceeds of approximately $17.6 million. This follows a public offering of 3,906,250 shares, which closed on June 15, 2020. With the additional shares, CareDx has sold a total of 4,492,187 shares, generating total net proceeds of around $134.7 million after expenses. The offering was managed by Goldman Sachs & Co. LLC and Jefferies LLC, among others.
CareDx, Inc. (Nasdaq: CDNA) has successfully closed a public offering of 3,906,250 shares of common stock priced at $32.00 per share, generating net proceeds of approximately $117.1 million. The underwriters also have a 30-day option to purchase an additional 585,937 shares. These funds are earmarked for working capital and general corporate purposes. The offering was conducted under a shelf registration statement, effective since June 9, 2020. Goldman Sachs & Co. LLC and Jefferies LLC served as joint book-running managers.
CareDx, Inc. (Nasdaq: CDNA) has announced the pricing of a public offering of 3,906,250 shares at $32.00 per share, aiming for gross proceeds of $125 million. The offering includes a 30-day option for underwriters to purchase an additional 585,937 shares. Expected to close around June 15, 2020, proceeds will support working capital and corporate purposes. The offering is registered under Form S-3ASR with the SEC. Goldman Sachs & Co. LLC and Jefferies LLC are leading the offering.
CareDx, Inc. (Nasdaq: CDNA) announced plans for an underwritten public offering of up to $100 million in its common stock. The company may grant underwriters a 30-day option to purchase an additional $15 million in shares. Proceeds will be used for working capital and general corporate purposes. The offering is contingent on market conditions and is being managed by Goldman Sachs & Co. LLC and Jefferies LLC. The offering is registered under a previously filed shelf registration statement with the SEC, and a preliminary prospectus will be available shortly.
CareDx, Inc. (Nasdaq: CDNA) announced an update regarding its 2020 Annual Meeting of Stockholders, which will now take place in a virtual format only due to COVID-19 restrictions. The meeting is scheduled for June 17, 2020, at 10:00 a.m. Pacific Time, and will cover the same agenda as previously communicated. Stockholders can still vote prior to the meeting using previously issued proxy materials. Instructions for attending the virtual meeting are provided, requiring a control number for stockholders, while guests can join with just their name and email.
CareDx, a precision medicine company focused on transplant patient solutions, announced its participation in the Goldman Sachs Global Healthcare Conference. The management will engage in a fireside chat on June 9, 2020, at 11:20 AM EDT. Interested stakeholders can access a live webcast through the company’s website. CareDx specializes in products and services that enhance the pre- and post-transplant experience, providing genomics-based information vital for transplant patients.
CareDx, Inc. (Nasdaq: CDNA) announced its participation in the Jefferies Virtual Healthcare Conference on June 3, 2020, at 11:00 AM EDT. The company, recognized for its precision medicine solutions for transplant patients, will provide a live webcast of its presentation available on its investor website. CareDx focuses on developing and commercializing high-value healthcare solutions and offers a range of products and services to support transplant patients and their caregivers.
CareDx, Inc. (Nasdaq: CDNA) has announced receiving CE mark approval for its AlloSeq Tx 17 technology, enhancing its availability for transplant patients, laboratories, and clinicians globally. This state-of-the-art solution offers superior donor organ matching and eliminates PCR disadvantages, improving workflow in Histocompatibility & Immunogenetics labs. Launched in September 2019, AlloSeq Tx 17 utilizes next-generation Hybrid Capture technology for HLA testing. CareDx aims to enhance patient care with genomics-based information, reinforcing its leadership in precision medicine for transplant solutions.
